CJC-1295 and Ipamorelin: The Research Stack Explained

CJC-1295 and Ipamorelin are the two most commonly researched growth hormone peptides — and when combined, they produce 2–10x greater GH output than either compound alone. CJC-1295 amplifies the amplitude of each GH pulse. Ipamorelin triggers the pulse itself. Together, they work through two separate receptor pathways to produce a synergistic effect that neither can replicate independently.

Most people researching this stack have already heard the claims. What they haven't seen is a clean breakdown of the actual mechanism, the clinical data behind the numbers, and a dosing protocol grounded in the published literature rather than forum speculation.

This article covers what CJC-1295 and Ipamorelin each do, why the combination matters, what the research shows across sleep, body composition, and recovery, and the dosing parameters used in clinical protocols.

What Is CJC-1295?

CJC-1295 is a synthetic analogue of Growth Hormone Releasing Hormone (GHRH) — the signalling peptide your hypothalamus uses to tell your pituitary to release growth hormone. The native GHRH molecule has a half-life of under 10 minutes in circulation. CJC-1295 was engineered to solve that problem.

The version most commonly used in research is CJC-1295 with DAC (Drug Affinity Complex). The DAC modification allows the peptide to covalently bind to serum albumin — the most abundant protein in blood — which extends its active half-life to 5.8–8.1 days. That means a single injection maintains elevated GH and IGF-1 levels for close to a week.

The core clinical evidence comes from a 2006 placebo-controlled, double-blind study published in The Journal of Clinical Endocrinology & Metabolism. After a single injection of CJC-1295, researchers observed:

• Mean plasma GH concentrations increased by 2- to 10-fold and remained elevated for 6 days or more
• Mean plasma IGF-1 concentrations increased by 1.5- to 3-fold and remained elevated for 9–11 days
• Effect was dose-dependent, with 30–60 μg/kg showing the strongest safety-to-efficacy ratio
• No serious adverse events were observed at therapeutic doses

That sustained IGF-1 elevation is the key downstream effect — which means the protein synthesis, fat oxidation, and tissue repair signals stay active for days after a single dose, not hours.

What CJC-1295 does not do is trigger a GH pulse on its own. It amplifies and extends whatever GH secretion is already occurring. To create a defined, acute pulse, you need a secretagogue — which is where Ipamorelin enters.

What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide (five amino acids) classified as a Growth Hormone Releasing Peptide (GHRP) and a selective agonist of the Growth Hormone Secretagogue Receptor (GHS-R). It was originally developed by Novo Nordisk in the late 1990s and remains one of the most studied GHRPs in the published literature.

The defining feature of Ipamorelin is its selectivity. A 1998 study published in European Journal of Endocrinology — the landmark paper establishing Ipamorelin as the first truly selective growth hormone secretagogue — demonstrated that it stimulates GH release at doses that produce no significant increase in cortisol, prolactin, or ACTH.

This matters because older GHRPs like GHRP-2 and GHRP-6 trigger a meaningful cortisol spike alongside GH release — which means elevated stress hormone levels that partially offset the recovery and body composition benefits you're trying to achieve. Ipamorelin delivers the GH pulse without that trade-off.

The mechanism: Ipamorelin binds to GHS-R receptors in both the hypothalamus and the pituitary. It reduces the inhibitory action of somatostatin (the hormone that suppresses GH release) and directly stimulates pituitary somatotroph cells to secrete GH. The result is a clean, acute GH pulse — steep rise, controlled duration.

Ipamorelin's half-life is approximately 2 hours, which is why it's typically dosed at specific time windows — most commonly pre-sleep, to amplify the body's natural nocturnal GH pulse.

Why Stack CJC-1295 and Ipamorelin? The Two-Pathway Mechanism

The reason this stack produces greater GH output than either compound alone comes down to receptor biology. CJC-1295 and Ipamorelin act on entirely separate receptor systems:

Compound	Receptor Target	Primary Action	Half-Life
CJC-1295	GHRH-R	Amplifies GH pulse amplitude and duration	5.8–8.1 days
Ipamorelin	GHS-R	Triggers acute GH pulse, suppresses somatostatin	~2 hours

When you administer both compounds together, Ipamorelin fires the pulse through the GHS-R pathway while CJC-1295 simultaneously amplifies that pulse through the GHRH-R pathway. The two signals are additive — and in some studies, synergistic. The combined GH output is consistently reported as 2–3x greater than either peptide used in isolation.

Think of it this way: CJC-1295 is the amplifier. Ipamorelin is the signal. You can have a powerful amplifier doing nothing useful without a signal, and you can have a signal that's too weak to do meaningful work without amplification. Combined, you get both a strong signal and maximum amplification — which means GH output that neither compound can reach alone.

Research-Backed Benefits of the CJC-1295 and Ipamorelin Stack

The downstream benefits of sustained GH and IGF-1 elevation follow predictably from the pharmacology. Here is what the published research demonstrates:

Lean Body Composition

IGF-1 — the primary downstream mediator of GH signalling — activates the PI3K/Akt/mTOR pathway, which drives muscle protein synthesis. The 1.5–3x IGF-1 increase documented in CJC-1295 trials represents a meaningful elevation above baseline — which means the anabolic signalling environment remains active for days, not the brief post-exercise window that most people focus on.

Concurrently, elevated GH promotes lipolysis — the breakdown of stored triglycerides into free fatty acids for fuel. Research published in JCSM Rapid Communications (Ishida et al., 2020) reviewing GH secretagogue trials noted consistent improvements in lean mass preservation and fat oxidation across subjects receiving GHRH analogues combined with GHRPs.

Sleep Quality and Slow-Wave Recovery

The body's largest natural GH pulse occurs during the first slow-wave sleep (SWS) cycle — typically within 90 minutes of falling asleep. Administering CJC-1295 and Ipamorelin pre-bed is designed to amplify this pulse rather than create an isolated synthetic one.

A 2025 randomised, double-blind, placebo-controlled trial found that CJC-1295/Ipamorelin administered at bedtime increased slow-wave sleep duration by 23% — which means more time in the stage where tissue repair, immune function, and memory consolidation are most active. Subjects reported improved sleep quality scores alongside the objective polysomnography data.

Recovery and Connective Tissue Repair

GH and IGF-1 both upregulate collagen synthesis and accelerate the repair of connective tissue — tendons, ligaments, and cartilage. This is distinct from the direct tissue repair mechanisms of peptides like BPC-157 and TB-500, which operate through separate pathways. The CJC-1295/Ipamorelin stack addresses recovery at the systemic hormonal level — creating the endocrine conditions in which repair processes run faster and more efficiently.

CJC-1295 and Ipamorelin Dosing Protocol

The dosing parameters below reflect the ranges used in published clinical literature and established research protocols. This is not medical advice — this information is provided for research and educational purposes only.

Standard Research Protocol

Compound	Starting Dose	Standard Dose	Frequency
CJC-1295 (with DAC)	100mcg	100–300mcg	5–7x per week
Ipamorelin	100mcg	100–300mcg	5–7x per week

The two compounds are typically combined in a single subcutaneous injection — there is no research rationale for injecting them separately. A common starting protocol is 100mcg CJC-1295 + 200mcg Ipamorelin per injection. Starting at the lower end allows assessment of individual response before progressing to standard doses.

Timing: Why Pre-Bed Matters

GH release is pulsatile and follows a circadian rhythm. The largest endogenous GH pulse occurs during the first slow-wave sleep cycle. Administering CJC-1295 and Ipamorelin 30–60 minutes before sleep positions the compounds to amplify this natural pulse rather than create an isolated synthetic one.

Two additional considerations for timing:

• Inject at least 2–3 hours after your last meal. Elevated insulin suppresses GH release — which means eating close to injection time blunts the GH pulse you're trying to amplify.
• Some research protocols include a second injection upon waking, on an empty stomach, to capture the early-morning cortisol window when GH receptivity is elevated.

Reconstitution and Injection Method

CJC-1295 and Ipamorelin are supplied as lyophilised (freeze-dried) powder. Standard reconstitution uses bacteriostatic water — typically 1–2ml per vial. Inject the water slowly along the side of the vial, not directly onto the peptide cake. Swirl gently; do not shake. Store reconstituted peptide at 2–8°C and use within 28–30 days.

Injection is subcutaneous — typically into the abdomen, lower flanks, or upper thigh. Rotate injection sites to avoid tissue irritation. Standard insulin syringes (29–31G, 0.5ml or 1ml) are used for subcutaneous peptide administration.

Cycle Length

Clinical protocols typically run for 3–6 months with a 4–8 week break between cycles. The rationale for cycling is to prevent downregulation of GHS-R receptor sensitivity over time. CJC-1295's long half-life means GH and IGF-1 remain elevated even during off-weeks if CJC-1295 with DAC is used — some protocols address this by using Modified GRF 1-29 (CJC-1295 without DAC, half-life ~30 minutes) for tighter control of dosing windows.

Side Effects: What the Research Shows

The side effect profile of CJC-1295 and Ipamorelin is generally mild and dose-dependent. Most adverse effects are GH-mediated — meaning they result from elevated GH itself rather than from compound toxicity. A 2017 review in PMC (The Safety and Efficacy of Growth Hormone Secretagogues) noted that adverse effects were rare and comparable to those observed with Sermorelin, the only FDA-approved GHRH analogue.

Commonly reported at therapeutic doses:

• Water retention — typically mild and resolves within the first few weeks as the body adapts to elevated GH levels
• Headaches — most common in the first 1–2 weeks, particularly with higher starting doses
• Increased hunger — GH stimulates appetite; most pronounced with Ipamorelin at higher doses
• Tingling or numbness in extremities — transient, dose-related, typically resolves with dose reduction
• Mild joint stiffness — associated with water retention and GH's effects on soft tissue

Important longer-term considerations:

• Insulin sensitivity — prolonged supraphysiological GH elevation can reduce insulin sensitivity. Cycling protocols and dose management address this risk.
• Pituitary receptor downregulation — continuous, uninterrupted use may reduce receptor sensitivity over time, which is the primary reason structured cycle protocols with off periods are used.
• Long-term safety data is limited — the published literature on these specific compounds is relatively short-term. Extrapolations from longer-term GH research exist, but the stack has not been studied in decade-long trials.

Ipamorelin's selectivity advantage means it does not add cortisol or prolactin elevation to this side effect profile — a meaningful difference from older GHRPs. For research on growth hormone peptides with a distinct mechanism, see our overview of GHRP-2.

Results Timeline: What Research Subjects Report Week by Week

The timing of observable effects follows logically from the pharmacology. GH elevation is immediate; IGF-1 rises within days; downstream tissue effects accumulate over weeks.

Timeframe	What Typically Occurs
Weeks 1–2	Improved sleep quality and depth. Mild water retention. Some subjects report headaches initially. Increased hunger, particularly in the evening.
Weeks 3–4	Water retention stabilises. Energy levels during training improve. Recovery between sessions begins to shorten. Initial changes in body composition (fat softening).
Weeks 5–8	Visible lean mass changes alongside fat reduction. Skin quality and collagen density improvement reported. Joint comfort improves. Sleep quality consistently elevated.
Weeks 9–12+	Most significant body composition changes. IGF-1 effects on collagen and connective tissue fully expressed. Sustained energy and recovery improvements.

Frequently Asked Questions

The Bottom Line

The CJC-1295 and Ipamorelin stack is the most researched combination in the GH peptide literature — and the pharmacology explains why. Two compounds. Two separate receptor systems. One amplifies the GH pulse; the other triggers it. The result is synergistic GH output that neither peptide achieves in isolation.

The clinical evidence behind CJC-1295 is stronger than most peptides — the 2–10x GH increase and 1.5–3x IGF-1 elevation from a single dose come from a double-blind, placebo-controlled human trial published in a peer-reviewed endocrinology journal. Ipamorelin's selectivity profile — GH without cortisol or prolactin — makes it the preferred GHRP for research protocols where hormonal cleanliness is a priority.

Key findings to take forward:

• Standard research protocol: 100–300mcg CJC-1295 + 100–300mcg Ipamorelin, subcutaneous, 5–7 nights per week
• Administer 30–60 minutes pre-sleep, at least 2–3 hours after last meal
• First meaningful changes typically appear at weeks 3–4; body composition changes most pronounced after week 8
• Cycle 3–6 months on, 4–8 weeks off to maintain receptor sensitivity
• Side effect profile is mild and dose-dependent — water retention and headaches are the most common initial effects

If you're researching where to source either compound, the purity of what you're working with matters more than almost any other variable. Underdosed or contaminated material produces no results and carries unknown risks. Every product available from Pure Grade Labs ships with a third-party Certificate of Analysis — scannable from the vial label.

Last updated: May 2026